Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test

Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test
·2 min read

Atea Pharmaceuticals said Tuesday its Merck-rivaling antiviral Covid pill missed in a midstage test, leading AVIR stock to crash.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting